Mirae Asset Global Investments Co. Ltd. Raises Stock Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 286.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 197,386 shares of the company's stock after buying an additional 146,303 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.10% of Sana Biotechnology worth $805,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Arizona State Retirement System increased its holdings in Sana Biotechnology by 12.2% during the 4th quarter. Arizona State Retirement System now owns 27,527 shares of the company's stock worth $112,000 after purchasing an additional 2,991 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Sana Biotechnology by 351.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company's stock worth $93,000 after buying an additional 17,753 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Sana Biotechnology in the 4th quarter valued at approximately $99,000. Vanguard Group Inc. lifted its stake in Sana Biotechnology by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,167,585 shares of the company's stock valued at $35,479,000 after acquiring an additional 107,167 shares in the last quarter. Finally, Citigroup Inc. boosted its position in Sana Biotechnology by 10.3% during the 3rd quarter. Citigroup Inc. now owns 145,370 shares of the company's stock worth $563,000 after acquiring an additional 13,616 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

SANA has been the subject of a number of recent research reports. HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Sana Biotechnology in a research note on Friday, March 1st. JMP Securities increased their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a "market outperform" rating in a research note on Friday, March 1st.

Insider Buying and Selling at Sana Biotechnology

In other news, Director Robert Nelsen acquired 1,818,181 shares of the firm's stock in a transaction on Thursday, February 8th. The shares were purchased at an average cost of $5.50 per share, with a total value of $9,999,995.50. Following the acquisition, the director now directly owns 12,446,022 shares in the company, valued at approximately $68,453,121. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 34.90% of the company's stock.

Sana Biotechnology Trading Down 0.9 %

NASDAQ:SANA traded down $0.08 during mid-day trading on Thursday, hitting $8.50. The stock had a trading volume of 1,825,504 shares, compared to its average volume of 3,032,742. Sana Biotechnology, Inc. has a twelve month low of $2.74 and a twelve month high of $12.00. The company's 50 day simple moving average is $9.07 and its 200 day simple moving average is $6.05.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.03. During the same period in the prior year, the company earned ($0.40) earnings per share. Sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.02 earnings per share for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.